Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity
ChemMedChem · 2024
DOI: 10.1002/cmdc.202400292 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Christian Gege und 12 weiteren Autor:innen. Beteiligte Einrichtung: Immunic AG, Lochhamer Schlag 21, 82166, Gräfelfing, Germany. Hauptthemen laut MEDLINE: Dihydroorotate Dehydrogenase, Antiviral Agents, SARS-CoV-2, Oxidoreductases Acting on CH-CH Group Donors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bavarian Research Foundation, Bayerische Forschungsstiftung.
Abstract (Originalsprache)
New strategies for the rapid development of broad‐spectrum antiviral therapies are urgently required for emerging and re‐emerging viruses like the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Host‐directed antivirals that target universal cellular metabolic pathways necessary for viral replication present a promising approach with broad‐spectrum activity and low potential for development of viral resistance. Dihydroorotate dehydrogenase (DHODH) was identified as one of those universal host factors essential for the replication of many clinically relevant human pathogenic viruses. DHODH is the rate‐limiting enzyme catalyzing the fourth step in the de novo pyrimidine synthesis. Therefore, it is also developed as a therapeutic target for many diseases relying on cellular pyrimidine resources, such as cancer, autoimmune diseases and viral or bacterial infection. Thus, several DHODH inhibitors, including vidofludimus calcium (VidoCa, IMU‐838), are currently in development or have been investigated in clinical trials for the treatment of virus infections such as SARS‐CoV‐2‐mediated coronavirus disease 19 (COVID‐19). Here, we report the medicinal chemistry optimization of VidoCa that resulted in metabolically more stable derivatives with improved DHODH target inhibition in various mammalian species, which translated into improved efficacy against SARS‐CoV‐2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunic AG, Lochhamer Schlag 21, 82166, Gräfelfing, Germany.
- Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054, Erlangen, Germany.
- Department of Vaccines and Infection Models, Unit Preclinical Validation, Fraunhofer-Institute for Cell Therapy and Immunology IZI, Perlickstrasse 1, 04103, Leipzig, Germany.
- Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, 14163, Berlin, Germany.
ORCID-Profile: Christian Gege
Förderung
- Bavarian Research Foundation
- Bayerische Forschungsstiftung
Zitieren
APA
Gege, C., Hahn, F., Wangen, C., Häge, S., Herrmann, A., Uhlig, N., Eberlein, V., Issmail, L., Klopfleisch, R., Grunwald, T., Marschall, M., Kohlhof, H., & Vitt, D. (2024). Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity. ChemMedChem. https://doi.org/10.1002/cmdc.202400292
Vancouver
Gege C, Hahn F, Wangen C, Häge S, Herrmann A, Uhlig N, et al. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity. ChemMedChem. 2024. doi:10.1002/cmdc.202400292
BibTeX
@article{Gege2024,
author = {Gege, Christian and Hahn, Friedrich and Wangen, Christina and Häge, Sigrun and Herrmann, Alexandra and Uhlig, Nadja and Eberlein, Valentina and Issmail, Leila and Klopfleisch, Robert and Grunwald, Thomas and Marschall, Manfred and Kohlhof, Hella and Vitt, Daniel},
title = {Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202400292}
}
EUVIMED